Mr. Ron Nagar reports

TEMPRAMED SIGNS LOI FOR EXCLUSIVE DISTRIBUTION IN KUWAIT, EXPANDING PRESENCE IN HIGH-GROWTH GULF REGION HEALTHCARE MARKET

Tempramed Technologies Ltd. has signed a non-binding letter of intent (LOI) dated June 30, 2026, with Elegir Trading regarding the exclusive distribution of Tempramed products in the State of Kuwait.

Highlights

• Tempramed signs non-binding LOI for exclusive distribution in Kuwait with Elegir Trading;
• Kuwait represents a high-value market with significant demand for insulin, GLP-1 therapies, biologics and other temperature-sensitive medications;
• LOI includes minimum annual purchase commitments in year 1;
• Expands Tempramed's footprint across the Middle East and supports broader regional commercialization strategy;
• Potential future expansion includes VIVI Med, VIVI Epi and VIVI Cap Smart products.

Under the contemplated agreement, Elegir Trading would initially distribute VIVI Cap, with the potential addition of VIVI Med, VIVI Epi and VIVI Cap Smart as the relationship expands. The proposed arrangement includes a three-year exclusive distribution framework with minimum annual purchase commitments in year 1.

The LOI forms part of Tempramed's broader strategy to expand across key international healthcare markets where high temperatures, increasing chronic disease prevalence and growing use of injectable therapies create strong demand for reliable medication-protection solutions.

Strong market potential in Kuwait and the Gulf region

Kuwait and the broader Gulf region represent an attractive market opportunity for Tempramed due to the combination of:

• Extremely high ambient temperatures throughout much of the year;
• High prevalence of diabetes and obesity;
• Rapid adoption of GLP-1 therapies for diabetes and weight management;
• Growing utilization of biologics and specialty injectable medications.

Patients across the Gulf region frequently face challenges maintaining medication efficacy during daily activities, commuting, travel and outdoor exposure. This creates a significant need for passive, portable and reusable thermal-protection technologies capable of safeguarding medications without refrigeration, batteries or external power.

Management believes Tempramed's technology platform is particularly well suited for the region given the real-world environmental conditions and the increasing use of high-value injectable therapies requiring strict temperature control.

"We continue to see strong global demand for practical solutions that protect temperature-sensitive medications in real-world conditions," said Ron Nagar, chief executive officer of Tempramed. "Kuwait represents an important strategic market due to its climate, health care infrastructure and rapidly growing use of injectable therapies such as insulin, GLP-1 medications and biologics. This LOI is another important step in expanding Tempramed's international commercial footprint."

About Elegir Trading

Elegir Trading was established to play a strategic role across multiple investment and health care sectors in Kuwait and the broader region. The company operates as a knowledge-based, results-oriented investment and commercialization organization, acting both as a direct investor and as a provider of corporate finance and execution capabilities.

Within health care, the company focuses on commercialization, market development and strategic business opportunities involving medical technologies and health care products. Management believes Elegir Trading's regional business network and diversified commercial capabilities position it well to support the introduction and growth of Tempramed products in Kuwait.

About Tempramed Technologies Ltd.

Tempramed Technologies is a global leader in innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, Tempramed develops patented, Food and Drug Administration-registered, space-grade thermal insulation devices that work 24/seven without batteries or external power. With a proven product line including VIVI Cap and VIVI Epi, and a smart technology platform on the horizon, Tempramed enables patients and health care providers to confidently manage temperature-sensitive medications anywhere, anytime. Headquartered in Israel with operations in North America, Europe and Asia, Tempramed is advancing the future of medication protection and adherence.

We seek Safe Harbor.